EPS for Intec Pharma Ltd. (NTEC) Expected At $-0.28 as of June, 8

May 17, 2018 - By Mary Markley

Intec Pharma Ltd. (NASDAQ:NTEC) Corporate Logo

Earnings report for Intec Pharma Ltd. (NASDAQ:NTEC) is anticipated on June, 8., as reported by Faxor. Analysts at Wall Street see Intec Pharma Ltd.’s -28.21 % EPS growth compared to $-0.39 earnings per share for last quarter. The last price was $4.85.Since May 17, 2017 it’s 25.00% up thus uptrending. The stock outperformed the S&P 500 by 13.45%.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel.The firm is worth $164.22 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.Currently it has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

Intec Pharma Ltd. (NASDAQ:NTEC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.